Skip to search formSkip to main contentSkip to account menu

Fasturtec

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Rasburicase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Spotlight on Rasburicase in Anticancer Therapy-Induced Hyperuricemia
Intravenous rasburicase (Elitek®, Fasturtec®) is the first recombinant uricolytic agent. It is indicated for the management of… 
2011
2011
Urate Oxidase Purification by Salting-in Crystallization: Towards an Alternative to Chromatography
Background Rasburicase (Fasturtec® or Elitek®, Sanofi-Aventis), the recombinant form of urate oxidase from Aspergillus flavus, is… 
Review
2008
Review
2008
SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) Recommendations for the Management of Tumor Lysis Syndrome (TLS) With Rasburicase: An Observational…
Rasburicase (Fasturtec), a recombinant urate oxidase, is highly effective in preventing and treating hyperuricemia in children… 
2006
2006
Efficacité et tolérance de la Rasburicase (Fasturtec®) chez des patients goutteux intolérants ou réfractaires à l'allopurinol
2005
2005
Actualités sur le traitement du syndrome de lyse tumorale Place de la rasburicase (Fasturtec
2004
2004
[Rasburicase (Fasturtec)].
Rasburicase (Fasturtec) is an enzyme that transforms uric acid to the more water soluble allantoin to be excreted by the kidneys… 
2002
2002
[New molecules in 2002].
Presentation et etude (d'apres les notices scientifiques) de 7 nouvelles molecules commercialisees au cours de ces derniers mois… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)